tradingkey.logo
tradingkey.logo
Search

Eli Lilly and Co

LLY
Add to Watchlist
1364.730USD
-53.260-3.76%
Close 11-05 16:00(ET)
1.28TMarket Cap
48.49P/E TTM
After-hours 19:38 (ET)1361.900USD-7.370-0.54%

Today

-3.76%

5 Days

+5.93%

1 Month

+19.41%

6 Months

+41.44%

Year to Date

+27.60%

1 Year

+48.34%

Key Figures

1434.000Open
1452.720High
2.12MVolume
48.49P/E TTM
28.33P/E Dynamic
6.230Dividend TTM
0.23%Turnover Ratio
1417.990Prev. Close
1365.560Low
2.98BTurnover
121.48P/E Static
31.95P/B
0.46%Div Yield TTM
24.54%ROA
1452.72052wk High
208.80Volume Ratio
10.59BNet Profit
940.75MShares
28.2003EPS TTM
0.52Beta
107.65%ROE
847.83352wk Low
6.15%Amplitude
83.95%Gross Margin
1.28TMarket Cap
1.64Reward/Risk
2.22%Risk Rate
Recent
Analysis
Earnings
Transcripts
Amgen Inc Stock (AMGN) Closed Down by 3.80% on Nov 5: What Investors Need To Know

• Amgen shares dropped despite beating third-quarter revenue and earnings consensus estimates. • Legacy franchises face accelerating sales declines from biosimilar competition and patent expirations. • Management flagged rising fourth-quarter operating expenditures and increased capital investment requirements.

TradingKey3 hours ago
Eli Lilly and Co Stock (LLY) Closed Down by 3.55% on Nov 5: A Full Analysis

• Eli Lilly shares declined due to valuation sensitivity and competitive metabolic dynamics. • Institutional profit-taking and macroeconomic cross-asset flows exacerbated the recent pullback. • The company maintains strong fundamentals, with $65.18 billion in annual revenue.

TradingKey3 hours ago
Gilead Sciences Inc Stock (GILD) Moved Down by 3.61% on Nov 5: What Investors Need To Know

• Gilead shares declined due to institutional profit-taking and technical consolidation after earnings. • Acquired research and development charges created headwinds for reported GAAP profitability. • Analysts maintain a buy rating with an average price target of $171.76.

TradingKey4 hours ago
AbbVie Inc Stock (ABBV) Closed Up by 3.09% on Nov 4: Key Drivers Unveiled

• AbbVie exceeded consensus estimates and raised its full-year guidance. • Skyrizi and Rinvoq drove strong double-digit sales expansion. • Multiple Wall Street firms raised their price targets.

TradingKeyWed, Nov 4
Merck & Co Inc Stock (MRK) Closed Up by 3.93% on Nov 4: Drivers Behind the Movement

• Merck raised full-year guidance following strong financial results and global demand. • Late-stage pipeline progress reinforced confidence in the company's growth strategy. • Analysts assigned an average price target of $157.01 with Buy ratings.

TradingKeyWed, Nov 4
Johnson & Johnson Stock (JNJ) Moved Up by 3.54% on Nov 4: A Full Analysis

• Johnson & Johnson reported positive clinical trial updates in MedTech and oncology portfolios. • The company exceeded quarterly earnings forecasts and reaffirmed its full-year earnings guidance. • Institutional stakeholders increased their positions amid favorable analyst ratings and technical buy signals.

TradingKeyWed, Nov 4

Eli Lilly and Co's Score

0.19vs previous score
Forecast8.30
Financial Health7.38
Technical6.04
Valuation Dimensions8.27
Institutional Confidence10.00
Risk Assessment8.83

Media Coverage

Coverage Level

50°C

Very Low
Very High
Positive+

Analyst Rating

Strong Buy
Buy
Hold
Sell
Strong Sell
BuyCurrent Rating
1404.183Target Price
-0.94%Upside Space
Current Rating2026-112026-102026-092026-082026-072026-062026-052026-04
Strong Buy1010101010101111
Buy1919171718171616
Hold33666778
Sell11111110
Strong Sell00000000

Eli Lilly and Co Technical Analysis

1m
5m
15m
30m
1h
2h
4h
D
W
M
1m
5m
15m
D
Technical Indicators
Sell
Summary
Buy
Moving Average
Strong buy

Eli Lilly and Co Latest Earnings Call Transcripts

Eli Lilly (LLY) Q3 2026 Earnings Call: Revenue Up 39%, Guidance Raised

Eli Lilly’s Q3 2026 earnings call covered 39% revenue growth, more than $16 billion from Mounjaro and Zepbound, and higher full-year guidance.

Financial Indicators

Currency: USD
Quarterly
Quarterly
Annual
Relevant data have not been disclosed by the company yet.
Currency: USD
Quarterly
Quarterly
Annual
Relevant data have not been disclosed by the company yet.

Earnings

Next reporting date
--
Reporting Period
2026Q3
Earnings / Forecast
7.23/6.26
Revenue / Forecast
24.40B/22.61B

Eli Lilly and Co Profile

SectorPharmaceuticals
Ticker SymbolLLY
Number of employees47000
CountryUnited States of America

Ownership

ShareholdersProportion
Lilly Endowment, Inc.9.76%
Vanguard Capital Management, LLC5.67%
PNC Investments LLC5.43%
BlackRock Institutional Trust Company, N.A.4.44%
Shareholder TypesProportion
Investment Advisor46.65%
Investment Advisor/Hedge Fund19.18%
Foundation9.76%
Research Firm2.14%

FAQs

What is the current price of Eli Lilly and Co (LLY)?

The current price of Eli Lilly and Co (LLY) is 1367.71.

What is the symbol of Eli Lilly and Co?

The ticker symbol of Eli Lilly and Co is LLY.

What is the 52-week high of Eli Lilly and Co?

The 52-week high of Eli Lilly and Co is 1452.72.

What is the 52-week low of Eli Lilly and Co?

The 52-week low of Eli Lilly and Co is 847.83.

What is the market capitalization of Eli Lilly and Co?

The market capitalization of Eli Lilly and Co is 1.29T.

Is Eli Lilly and Co (LLY) currently rated as Buy, Hold, or Sell?

According to analysts, Eli Lilly and Co (LLY) has an overall rating of Buy, with a price target of 1404.18.

What is the Earnings Per Share (EPS TTM) of Eli Lilly and Co (LLY)?

The Earnings Per Share (EPS TTM) of Eli Lilly and Co (LLY) is 28.20.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.